Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pharmaxis grants BI option on NASH program PXS4728A; option exercised

Executive Summary

For a fee of €1.25mm ($1.33mm), Pharmaxis Ltd. granted Boehringer Ingelheim GMBH an option to license exclusive worldwide rights to its Phase I nonalcoholic steatohepatitis (NASH) candidate PXS4728A, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1 (VAP-1)).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register